Rituximab used for treatment of lymphoma is an antibody drug of which target is pan-B cell marker, CD20. It has been reported that the C-terminal region of CD20 undertakes a critical role in a binding to rituximab and the association between C-terminal mutations and rituximab-resistance has been investigated. This antibody was developed as a new monoclonal antibody that recognizes the N-terminal region of CD20 molecule to detect comprehensive CD20 regardless of C-terminal mutations. It is expected to be useful for the detailed examination of CD20 molecules by adding this antibody to research of CD20. For research use only, not for use in diagnostic procedures.
- application:
- IHC, WB
- Catalog number:
- 10415-S
- clone:
- 4-6H:2C
- concentration:
- Please see datasheet
- Datasheet:
- formulation:
- Lyophilized product from 1.0 mL of PBS containing 1% BSA and 0.05% NaN3
- immunogen:
- Synthetic peptide of the N-terminal part of human CD20 (CMQSGPKPLFRRMSS)
- isotype:
- IgG3
- MSDS:
- notes:
- For research use only, not for use in diagnostic procedures.
The datasheet for this product (see above) is intended to serve as an example only. Please refer to the datasheet provided with the antibody for precise details. - Other names:
- Please see datasheet
- size:
- 10 µg
- storage:
- Lyophilized product, 5 years at 2 - 8 °C; Solution, 2 years at -20 °C
- Species:
- Human
- Host:
- Mouse
